Sevelamer versus calcium-based phosphate binders for chronic kidney disease

Bravo-Soto et al., 2017 | Medwave | Meta Analysis

Citation

Bravo-Soto Gonzalo A, Madrid Trinidad. Sevelamer versus calcium-based phosphate binders for chronic kidney disease. Medwave. 2017-May-12;17(Suppl2):e6942. doi:10.5867/medwave.2017.6942

Abstract

Chronic kidney disease-mineral and bone disorder is prevalent. There is controversy regarding whether calcium-based phosphate binders or sevelamer - a non-calcium phosphate binder constitute a better therapeutic alternative. Searching in Epistemonikos database, which is maintained by screening multiple information sources, we identified 12 systematic reviews comprising 61 studies of which 41 correspond to randomized trials addressing the question of this article. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded sevelamer may decrease hypercalcemia, but with a higher incidence of gastrointestinal effects than calcium based phosphate binders. It is unclear if there are differences in mortality because the certainty of the evidence is very low.

Key Findings

It is unclear if there are differences in mortality because the certainty of the evidence is very low.

Outcomes Measured

Requires manual extraction

Population

Field	Value
Population	See abstract
Sample Size	61
Age Range	See abstract
Condition	See abstract

MeSH Terms

Calcium Compounds
Chelating Agents
Chronic Kidney Disease-Mineral and Bone Disorder
Databases, Factual
Humans
Hypercalcemia
Phosphates
Randomized Controlled Trials as Topic
Sevelamer

Evidence Classification

Level: Meta Analysis
Publication Types: Comparative Study, Journal Article, Meta-Analysis
Vertical: phosphorus

Provenance

PMID: 28525528
DOI: 10.5867/medwave.2017.6942
PMCID: Not in PMC
Verified: 2026-04-10 via PubMed E-utilities API

Source extracted via PubMed E-utilities API on 2026-04-10